Cardiology panels
From evidence to practice: Narrowing the gap
Dr Keith Fox talks to Drs Gregg Stone and Robert Harrington about why it takes so long for new evidence-based therapies to be adopted in clinical practice, the importance of national registries, and what can be done to make treatment guidelines more useful.
Genetic beta-blockade
What are the implications of an exciting discovery of intrinsic genetic beta-blockade common to 40% of people of African ancestry?

Dr Eric Topol invites you to share your opinions.

Click here to view the video blog and join the discussion.

HeartWire clips
On moving to industry: Interview with Dr Terry Ferguson
In conversation with heartwire news and features editor Larry Husten, Dr Terry Ferguson muses on changes to daily life, decision making processes, and patient care from a different perspective resulting from his new position in industry.
The Cardiology Show
Surrogate end points on trial: ENHANCE and other controversies
Part 2 is now live!
Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the American College of Cardiology Scientific Sessions.

Dr Valentin Fuster moderates this frank and sometimes heated discussion on the results of ENHANCE, STRADIVARIUS, ONTARGET, and PERISCOPE, and the questions they raise about the responsibility of industry and the relevance of surrogate end points.
Forum
Smoking ban?
Read about our forum moderator's heroic and sometimes comic efforts to get a smoking ban passed by her city council in tobacco country.
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join Drs Eric J Topol and Robert M Califf in a discussion of the many issues surrounding ENHANCE and ACCORD.
Question
Do you think the ACC and SCAI should continue to combine their annual meetings in future years?
(See:Arranged marriage: Funding and "cultural differences" may dictate whether SCAI-ACC/i2 stay hitched)
No
Yes
Vote








Abdominal obesity
Cardiometabolic risk in the spotlight: Which therapies should take center stage?
Dec 18, 2007 13:39 EST / Drs Smith, Rader, Nesto, Plutzky, Nemeroff, and Pagotto explore the interrelated role of cardiometabolic risk factors and analyze the mechanism of action and evidence for the effectiveness of cannabinoid receptor type 1 (CB1) blockade in CVD.
Taming abdominal obesity: Preventing the attack of CVD and diabetes
Nov 21, 2007 10:45 EST / Recent studies reveal that weight loss can directly decrease CV mortality and increase longevity. How do clinicians determine the right combination of therapies to promote weight loss and decrease risk factors associated with CVD and diabetes? Join our international faculty for this stimulating discussion.
Abdominal obesity: The perfect storm of CVD and diabetes
Nov 16, 2007 15:00 EST / Should clinicians intervene for "overweight" patients or just for the "obese" regarding risk of CVD and diabetes? Does abdominal obesity create the perfect storm for catastrophic events? Join Professors Deanfield and Steg as they examine these questions through case study review.
Dysglycemia
EASD 2007: Keys to prevention in diabetes and CV risk
Oct 17, 2007 15:30 EDT / The incidence of type 2 diabetes worldwide has increased from 30 million to 246 million over the last two decades, and continues to escalate. Some studies have revealed that approximately 80% of people with diabetes die of cardiovascular complications. This program will capitalize on cardiovascular risk, glycemic control and genetics influencing prevention and treatment in diabetes.
Test your knowledge on risk assessment and intervention for patients with dysglycemia
Aug 30, 2007 15:40 EDT / Did you know that people with prediabetes have a 1.5-fold increased risk of CV disease compared to individuals with normal glucose levels? Are you aware that the presence of diabetes alone can make one 5 times more likely to die from heart disease? Consider the likelihood if other risk factors are present. Are you doing all that you can to minimize your patients CV risk? Test your knowledge regarding risk assessment and intervention for patients with dysglycemia.
Charting the course of CV risk in diabetes: Case study analysis
Jun 28, 2007 16:35 EDT / People with prediabetes have a 1.5-fold increased risk of cardiovascular disease compared to those with normal glucose levels. Once diabetes develops, CV complications frequently occur at an earlier age, resulting in premature death. Are we overlooking "warning signals" that CV injury is imminent? Join Drs Nesto and Hollander for this intriguing case study review.
Other programs


Heartwire - Cardiometabolic risk - Latest news